Search Bar & Filters
Found 150 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of a drug called arumakimig MAS825 compared to a placebo in adults with VEXAS syndrome, a rare autoinflammatory condition linked to a mutation in the UBA1 gene. This study is a Phase 2, randomized, double-blind trial focused on participants who are also receiving glucocorticoids. The goal is to assess key disease improvements and the ability to reduce oral glucocorticoid use over 52 weeks. Participants will be randomly assigned to receive either arumakimig or placebo injections for 52 weeks while continuing glucocorticoid therapy, with the option to taper glucocorticoids after the first two weeks based on disease status. After this double-blind phase, eligible participants may enter a 2-year open-label extension to receive arumakimig until Week 156. Following the treatment periods, a 16-week safety follow-up is conducted to monitor long-term safety and tolerability. During the trial, participants will undergo assessments to measure improvements in VEXAS manifestations, glucocorticoid reduction, overall clinical response, flare-free days, and hematologic improvements. Safety will be closely monitored through adverse event tracking up to Week 172. Participants will also complete questionnaires about their disease status. The total participation duration can extend up to approximately three years including treatment, extension, and follow-up periods.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
Actively Recruiting
Researchers are studying MK-7262, a trial medicine designed to lower Lipoproteina Lpa levels in the blood. The study aims to learn about the effects of MK-7262 alone and in combination with another trial medicine called enlicitide, which belongs to a group of medicines that lower low-density lipoprotein cholesterol LDL-C. This Phase 2 clinical trial evaluates the ability of these medicines to reduce Lpa and LDL-C levels and assesses their safety and tolerability. Participants will be randomly assigned to one of four groups MK-7262 with enlicitide, MK-7262 alone, enlicitide alone, or placebo for both medicines. All treatments are given orally once daily for up to approximately 12 weeks. The study is double-blind with placebo controls, and the medicines are taken as coated tablets. The trial monitors effects at specific time points including weeks 8 and 12. During the trial, participants will undergo blood tests to measure changes in Lpa and LDL-C levels from baseline. Researchers will track adverse events and monitor safety for up to about 20 weeks. The primary outcomes include percent changes in Lpa and LDL-C at week 8 and the number of participants experiencing side effects or discontinuing treatment due to side effects. Participation lasts for the treatment period and follow-up assessments.
Actively Recruiting
Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
This research aims to observe and track growth patterns and the clinical progression of Hypochondroplasia HCH in children. It focuses on collecting various growth measurements and other relevant data over time to better understand this condition. The study is sponsored by BioMarin Pharmaceutical and involves children diagnosed with Hypochondroplasia, up to 15 years old. Participants include children confirmed to have Hypochondroplasia through genetic testing. The study is observational, meaning there are no experimental treatments involved. Children will be monitored regularly to record changes in growth and body proportions, with data collection occurring every six months over the course of the study, which may last up to 15 years. Throughout the study, children will undergo assessments every six months to measure growth velocity, height, body mass index BMI, and body segment ratios. Quality of life and severity impressions from both patients and caregivers will be evaluated annually. Researchers will also track medical events, use of growth hormone treatments, and any limb lengthening surgeries. This long-term follow-up allows for comprehensive monitoring of growth and health outcomes in children with Hypochondroplasia.
Actively Recruiting
This research focuses on patients who developed secondary malignancies of T-cell origin after receiving tisagenlecleucel treatment. It aims to understand if tisagenlecleucel plays a role in the development of these secondary cancers. The study includes individuals treated either in clinical trials or in commercial settings who have confirmed secondary T-cell malignancies. Participants are grouped into two cohorts one from clinical trial settings who discontinued prior studies or long-term follow-up, and another from post-marketing or commercial use, including those treated under special access programs. No new treatments are given, as this is an observational study collecting existing tissue and blood samples for analysis over approximately 15 years. During the study, researchers will analyze available tumor tissue and blood DNA samples to test for specific markers related to tisagenlecleucel. They will measure factors such as vector copy number and test for replication-competent lentivirus. Consent is required, and samples come from routine care. The study will track these measures at screening and continue to enroll eligible participants over many years.
Actively Recruiting
Researchers are evaluating the drug elacestrant in Japanese post-menopausal women and men with advanced or metastatic breast cancer that is estrogen receptor positive ER and human epidermal growth factor receptor 2 negative HER2-, who also have a specific gene mutation known as ESR1. These participants must have experienced disease progression after 1 to 2 prior endocrine therapy treatments for metastatic breast cancer, including therapy with a CDK46 inhibitor combined with fulvestrant or an aromatase inhibitor. The study is an open-label Phase 2 trial aimed at assessing elacestrants efficacy and safety. Participants will receive elacestrant as a once-daily oral tablet. This is a single-arm study without a placebo group, focusing on treatment with elacestrant. The study will continue for up to approximately 27 months to monitor treatment effects and safety. During the study, participants will undergo evaluations including imaging assessments to measure progression-free survival, adverse event monitoring, and blood tests to measure plasma concentrations of elacestrant. Researchers will also observe overall survival and progression-free survival as assessed by investigators. The total duration for participant involvement aligns with the treatment and follow-up period of up to about 27 months.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
1-10 of 150
1